Secnidazole - Evofem Biosciences
Alternative Names: Solosec; SYM-1219Latest Information Update: 31 Oct 2025
At a glance
- Originator Symbiomix Therapeutics
- Developer Evofem Biosciences; Lupin; Symbiomix Therapeutics
- Class Antibacterials; Antiprotozoals; Nitroimidazoles; Propanols; Small molecules
- Mechanism of Action DNA synthesis inhibitors; Free radical stimulants
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Bacterial vaginosis; Trichomoniasis
Most Recent Events
- 01 Oct 2025 Pharma 1 files a marketing application with the UAE Ministry of Health and Prevention in the United Arab Emirates for Secnidazole for Bacterial vaginosis and Trichomoniasis
- 01 Oct 2025 Preregistration for Bacterial vaginosis in United Arab Emirates (PO)
- 01 Oct 2025 Preregistration for Trichomoniasis in United Arab Emirates (PO)